Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Humacyte ( (HUMA) ).
On March 19, 2026, Humacyte, Inc. entered into securities purchase agreements for a registered direct offering of 25,000,000 shares of common stock at $0.80 per share, for expected net proceeds of about $18.4 million. The deal, led by a new life science–focused investor and a long-only mutual fund with Titan Partners as sole placement agent, is expected to close around March 20, 2026, subject to customary conditions.
The gross proceeds of roughly $20 million are earmarked to fund commercialization of Symvess in the vascular trauma indication, support a planned Biologics License Application supplement in hemodialysis and related Phase 3 activities, advance pipeline development, and bolster working capital and general corporate needs. The capital raise underscores Humacyte’s push to scale its first commercial product and progress its bioengineered tissue platform at a pivotal clinical and regulatory juncture.
The most recent analyst rating on (HUMA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Humacyte stock, see the HUMA Stock Forecast page.
Spark’s Take on HUMA Stock
According to Spark, TipRanks’ AI Analyst, HUMA is a Neutral.
The score is held down primarily by weak financial performance (large losses, heavy cash burn, and negative equity) and bearish technicals (price below key moving averages with negative MACD). Offsetting factors include a more constructive earnings call with improving commercial traction and reduced net loss, plus recent financing/loan facilities that extend runway, but valuation remains difficult due to negative earnings.
To see Spark’s full report on HUMA stock, click here.
More about Humacyte
Humacyte, Inc. is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. The company’s first FDA-approved product, Symvess, was commercially launched in the United States in the first quarter of 2025 for extremity vascular trauma, and Humacyte is advancing a broader pipeline of acellular tissue-engineered vessels and constructs across multiple therapeutic areas.
The company aims to address long-standing gaps in tissue repair, reconstruction and replacement by offering off-the-shelf, regenerative medicine solutions designed to overcome limitations of existing standards of care. Its technology platform is intended to support development of advanced tissue constructs and organ systems for a range of diseases and anatomic locations, positioning Humacyte as a specialized player in the emerging field of bioengineered human tissues.
Average Trading Volume: 5,189,256
Technical Sentiment Signal: Sell
Current Market Cap: $204.6M
Learn more about HUMA stock on TipRanks’ Stock Analysis page.